GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) | GRAL Stock News

    Date:

    MENLO PARK, Calif., Aug. 30, 2024 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units (“RSUs”) underlying an aggregate of 182,223 shares of GRAIL’s common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

    The RSUs vest over an approximately four year period, with 25% of the award vesting in either May or August, 2025, depending on the start date of the employee, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

    About GRAIL
    GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

    For more information, visit grail.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302235336.html

    SOURCE GRAIL, Inc.

    Go Source

    Chart

    SignUp For Breaking Alerts

    New Graphic

    We respect your email privacy

    Share post:

    Popular

    More like this
    Related

    Trump Taps Liberty Energy CEO Chris Wright For Energy Secretary

    President-elect Donald Trump has selected Chris Wright, a prominent...

    Kim Jong Un Pushes Mass Production Of Exploding Drones

    North Korean leader Kim Jong Un has supervised the...

    Interior Pick Burgum Named Trump’s Energy Czar

    President-elect Donald Trump has made several key appointments to...

    Bill Clinton Recalls Trump’s Actions On January 6

    In a soon-to-be-published book, former President Bill Clinton recounts...